Please use this identifier to cite or link to this item:
https://nslhd.intersearch.com.au/nslhdjspui/handle/1/42913| Title: | Publisher Correction: Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial | Authors: | Harbeck, Nadia;Ciruelos, Eva;Jerusalem, Guy;Müller, Volkmar;Niikura, Naoki;Viale, Giuseppe;Bartsch, Rupert;Kurzeder, Christian;Higgins, Michaela J;Connolly, Roisin M;Baron-Hay, Sally E ;Gión, María;Guarneri, Valentina;Bianchini, Giampaolo;Wildiers, Hans;Escrivá-de-Romaní, Santiago;Prahladan, Manoj;Bridge, Helen;Kuptsova-Clarkson, Nataliya;Scotto, Nana;Verma, Sunil;Lin, Nancy U | Affiliation: | Breast Center, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Munich, LMU University Hospital, Munich, Germany. nadia.harbeck@med.uni-muenchen.de. Hospital Universitario 12 de Octubre, Madrid, Spain. CHU Liège and Liège University, Liège, Belgium. University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Tokai University School of Medicine, Kanagawa, Japan. Department of Pathology and Laboratory Medicine, IEO European Institute of Oncology IRCCS, Milan, Italy. Division of Oncology, Department of Medicine 1, Medical University of Vienna, Vienna, Austria. Breast Center, University Hospital Basel, Basel, Switzerland. St. Vincent's University Hospital, UCD Cancer Trials Cluster, Dublin, Ireland. Cancer Research @UCC, College of Medicine and Health, University College Cork, Cork, Ireland.;Cancer Trials Cork, CUH/UCC Cancer Center, Cork University Hospital, Cork, Ireland. Royal North Shore Hospital IOB-Madrid, Beata María Ana Hospital, Madrid, Spain.;Department of Medical Oncology, Ramón y Cajal University Hospital, Madrid, Spain. Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.;Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy. Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.;School of Medicine and Surgery, Vita-Salute San Raffaele University, Milan, Italy. Department of General Medical Oncology, University Hospitals Leuven, KU Leuven, Leuven, Belgium. Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain. Global Medical Affairs, Oncology R&D, AstraZeneca, Cambridge, UK. Oncology Global Medical Affairs / Payer Biometrics, AstraZeneca, Macclesfield, UK. Patient Safety, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA. Oncology Global Medical Affairs, AstraZeneca, Baar, Switzerland. Oncology Franchise, AstraZeneca, Gaithersburg, MD, USA. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. |
Department: | Medical Oncology | Issue Date: | Dec-2024 | Publication information: | 30(12):3780 | Journal: | Nature Medicine | URI: | https://nslhd.intersearch.com.au/nslhdjspui/handle/1/42913 | DOI: | 10.1038/s41591-024-03349-0 | URL: | https://pmc.ncbi.nlm.nih.gov/articles/PMC11645286/ | ISSN: | 1546-170X | Type: | Other |
| Appears in Collections: | Research Publications |
Show full item record
Items in NSLHD are protected by copyright, with all rights reserved, unless otherwise indicated.